Şuşman Sergiu, Leucuţa Daniel-Corneliu, Kacso Gabriel, Florian Ştefan Ioan
Department of Morphological Sciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of Neuropathology-Imogen Research Center, Emergency County Hospital, Cluj-Napoca, Romania.
Cancer Manag Res. 2019 Jul 18;11:6741-6753. doi: 10.2147/CMAR.S206033. eCollection 2019.
The published data indicate that the irradiation of the subventricular zone (SVZ) might play a role in the treatment of patients with glioblastoma (GBM). We aimed to determine whether radiation treatment doses (high vs low) applied to the SVZ can lead to an increase in progression free survival (PFS) and overall survival (OS).
We undertook a systematic review and meta-analysis according to the PICOS research criteria of patients with glioblastoma which received high doses compared to low doses in order to determine if they have a better survival in observational and experimental studies.
Our survey of the literature yielded 2573 unique records. After screening, 17 were assessed for eligibility, and in the end 8 were included in the qualitative and 4 in the quantitative analysis. Subjects who received higher doses of ipsilateral SVZ (iSVZ) irradiation had a statistically significant better PFS than those receiving lower doses (HR 0.58 [95% CI 0.42-0.82], =0.002). Subjects receiving higher doses of contralateral SVZ (cSVZ) irradiation did not have a statistically significant better PFS than those receiving lower doses (HR =0.89 [95% CI 0.35-2.26], =0.81). Also for OS the subjects receiving higher doses to the iSVZ did not have a statistically significant better survival than those receiving lower doses (HR =0.75 [95% CI 0.51-1.11], =0.15).
The data indicate a possible involvement of the SVZ in the onset and progression of the GBM, as well as a possible role of the SVZ in radiation therapy.
已发表的数据表明,脑室下区(SVZ)的照射可能在胶质母细胞瘤(GBM)患者的治疗中发挥作用。我们旨在确定应用于SVZ的放射治疗剂量(高剂量与低剂量)是否会导致无进展生存期(PFS)和总生存期(OS)增加。
我们根据PICOS研究标准对接受高剂量与低剂量治疗的胶质母细胞瘤患者进行了系统评价和荟萃分析,以确定他们在观察性和实验性研究中是否具有更好的生存期。
我们对文献的检索产生了2573条独特记录。筛选后,评估了17条记录的 eligibility,最终8条纳入定性分析,4条纳入定量分析。接受同侧SVZ(iSVZ)高剂量照射的受试者的PFS在统计学上显著优于接受低剂量照射的受试者(HR 0.58 [95% CI 0.42 - 0.82],P = 0.002)。接受对侧SVZ(cSVZ)高剂量照射的受试者的PFS在统计学上并不显著优于接受低剂量照射的受试者(HR = 0.89 [95% CI 0.35 - 2.26],P = 0.81)。同样对于OS,接受iSVZ高剂量照射的受试者的生存期在统计学上并不显著优于接受低剂量照射的受试者(HR = 0.75 [95% CI 0.51 - 1.11],P = 0.15)。
数据表明SVZ可能参与GBM的发生和进展,以及SVZ在放射治疗中可能发挥的作用。